id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1825-0015,FDA,FDA-2020-D-1825,Investigational COVID-19 Convalescent Plasma Guidance for Industry,Other,Guidance,2020-12-29T05:00:00Z,2020,12,2021-01-04T05:00:00Z,,2024-11-06T23:44:24Z,,1,0,09000064849dc6c4
FDA-2020-D-1825-0011,FDA,FDA-2020-D-1825,Investigational COVID–19 Convalescent Plasma; Guidance for Industry; Withdrawal of Guidance,Notice,Withdrawal,2020-09-21T04:00:00Z,2020,9,2020-09-21T04:00:00Z,,2020-09-21T13:08:30Z,2020-20801,0,0,090000648486a83b
FDA-2020-D-1825-0008,FDA,FDA-2020-D-1825,Ref 6 - Leider re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:48Z,,0,0,090000648486aafd
FDA-2020-D-1825-0007,FDA,FDA-2020-D-1825,Ref 5 - Cheng re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:40Z,,0,0,090000648486aafc
FDA-2020-D-1825-0009,FDA,FDA-2020-D-1825,Ref 7 - Arabi re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:55Z,,0,0,090000648486aafe
FDA-2020-D-1825-0002,FDA,FDA-2020-D-1825,Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Other,Guidance,2020-09-21T04:00:00Z,2020,9,2020-09-21T04:00:00Z,,2024-11-06T23:39:27Z,,1,0,090000648486aaec
FDA-2020-D-1825-0004,FDA,FDA-2020-D-1825,Ref 2 re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:18Z,,0,0,090000648486aaf9
FDA-2020-D-1825-0005,FDA,FDA-2020-D-1825,Ref 3 - Chen re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:25Z,,0,0,090000648486aafa
FDA-2020-D-1825-0010,FDA,FDA-2020-D-1825,Ref 8 re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:02:03Z,,0,0,090000648486aaff
FDA-2020-D-1825-0006,FDA,FDA-2020-D-1825,Ref 4 - Duan re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:01:32Z,,0,0,090000648486aafb
FDA-2020-D-1825-0003,FDA,FDA-2020-D-1825,Ref 1 re Investigational COVID-19 Convalescent Plasma; Guidance for Industry,Supporting & Related Material,Background Material,2020-09-21T04:00:00Z,2020,9,,,2020-09-21T13:00:56Z,,0,0,090000648486aaf8
FDA-2020-D-1825-0001,FDA,FDA-2020-D-1825,Investigational COVID–19 Convalescent Plasma; Guidance for Industry; Availability,Notice,Notice of Availability,2020-09-21T04:00:00Z,2020,9,2020-09-21T04:00:00Z,,2020-09-21T12:26:26Z,2020-20800,0,0,090000648486a761